Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> CP-91149 [186392-40-5]

CP-91149 [186392-40-5]

Stampa Stampa
Entra

Cat# HY-13525-10mg

Size : 10mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CP-91149 Chemical Structure

CP-91149 Chemical Structure

CAS No. : 186392-40-5

This product is a controlled substance and not for sale in your territory.

Based on 4 publication(s) in Google Scholar

Description

CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study[1].

In Vitro

CP-91149 treatment decreases muscle GP activity by converting the phosphorylated AMP-independent α form into the dephosphorylated AMP-dependent b form and inhibiting GP α activity and AMP-mediated GP b activation[1].
CP-91149 (10, 30, 50 μM) inhibits brain GP and causes glycogen accumulation in A549 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CP-91149 Related Antibodies

Cell Viability Assay[1]

Cell Line: Cells were transduced with adenoviruses and incubated in the presence of 25 mM glucose for 2 days.
Concentration: 10 µM (glucose− or glucose+ for 18 h).
Incubation Time: 3 h.
Result: Promoted the conversion of GP a into GP b, according to α model proposed in hepatocytes.

Western Blot Analysis[2]

Cell Line: A549 cells.
Concentration: 0, 10, 30, 50 μM.
Incubation Time: 72 h.
Result: A significant increase in glycogen accumulation was detected at 10 μM of CP-91149 as compared with untreated cells with a maximal glycogen accumulation at 30 μM. Intracellular glycogen content decreased at 50 μM CP-91149, perhaps explained by additional pharmacological effects of the drug. The dose-dependent accumulation of intracellular glycogen in A549 cells by CP-91149 indicates that CP-91149 inhibits brain GP in tissue culture.
Masse moléculaire

399.87

Formule

C21H22ClN3O3
CAS No.

186392-40-5
Appearance

Solid

Color

White to off-white

SMILES

O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N[C@@H](CC3=CC=CC=C3)[C@@H](O)C(N(C)C)=O
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (250.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5008 mL 12.5041 mL 25.0081 mL
5 mM 0.5002 mL 2.5008 mL 5.0016 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
Références

  • [1]. Carlos Lerín, et al. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. 2004 Mar 15; 378(Pt 3): 1073–1077.

  • [1]. Carlos Lerín, et al. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. 2004 Mar 15; 378(Pt 3): 1073–1077.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5008 mL 12.5041 mL 25.0081 mL 62.5203 mL
5 mM 0.5002 mL 2.5008 mL 5.0016 mL 12.5041 mL
10 mM 0.2501 mL 1.2504 mL 2.5008 mL 6.2520 mL
15 mM 0.1667 mL 0.8336 mL 1.6672 mL 4.1680 mL
20 mM 0.1250 mL 0.6252 mL 1.2504 mL 3.1260 mL
25 mM 0.1000 mL 0.5002 mL 1.0003 mL 2.5008 mL
30 mM 0.0834 mL 0.4168 mL 0.8336 mL 2.0840 mL
40 mM 0.0625 mL 0.3126 mL 0.6252 mL 1.5630 mL
50 mM 0.0500 mL 0.2501 mL 0.5002 mL 1.2504 mL
60 mM 0.0417 mL 0.2084 mL 0.4168 mL 1.0420 mL
80 mM 0.0313 mL 0.1563 mL 0.3126 mL 0.7815 mL
100 mM 0.0250 mL 0.1250 mL 0.2501 mL 0.6252 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CP-91149 Related Classifications

  • Others
  • Others
Help & FAQs

Keywords:

CP-91149186392-40-5CP91149CP 91149OthersNSCLCA549diabetesInhibitorinhibitorinhibit

Si può anche essere interessati nei seguenti prodotti:



Cat#
Descrizione
Cond.
Priced
331-21713-2
TCEP hydrochloride
 10g